WHANIN PHARM CO.,LTD Logo

WHANIN PHARM CO.,LTD

Develops and sells pharmaceuticals, specializing in CNS, cardiovascular, and GI drugs.

016580 | KO

Overview

Corporate Details

ISIN(s):
KR7016580003
LEI:
Country:
South Korea
Address:
서울특별시 송파구 법원로6길 11 (문정동, 환인빌딩), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Whanin Pharm Co., Ltd. is a pharmaceutical company focused on the development, manufacturing, and sale of therapeutic products. The company specializes in medications for the Central Nervous System (CNS), offering a range of neuropsychiatric drugs including anti-depressants, anti-psychotics, and nootropics. In addition to its core CNS portfolio, Whanin Pharm also produces pharmaceuticals for other therapeutic categories such as cardiovascular and gastrointestinal treatments, as well as antibiotics. The company actively engages in research and development to create innovative medications, extending its focus beyond CNS to the broader healthcare sphere.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.7 MB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-08-01 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.9 KB
2025-07-11 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 19.7 KB
2025-07-07 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 30.6 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-04-30 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.9 KB
2025-03-21 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.8 KB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.9 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 20.1 KB
2025-03-13 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.8 MB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 830.1 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.9 KB
2025-02-28 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 8.4 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.7 KB

Automate Your Workflow. Get a real-time feed of all WHANIN PHARM CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for WHANIN PHARM CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for WHANIN PHARM CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Oramed Pharmaceuticals Inc. Logo
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel
ORMP
ORASURE TECHNOLOGIES INC Logo
Develops and distributes point-of-care diagnostic tests and sample collection devices.
United States of America
OSUR
Orexo Logo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
Sweden
ORX
ORGANIGRAM GLOBAL INC. Logo
Licensed producer of indoor-grown cannabis and derived products for medical & recreational consumers.
United States of America
OGI
Organon & Co. Logo
A global healthcare company focused on women's health, biosimilars, and established brands worldwide.
United States of America
OGN
Oric Pharmaceuticals, Inc. Logo
Developing therapies to overcome resistance in lung and prostate cancer.
United States of America
ORIC
Orion Oyj Logo
Develops and manufactures human/vet pharma, APIs, and generics for global markets.
Finland
ORNAV
Oruka Therapeutics, Inc. Logo
Develops long-acting antibody therapies for chronic inflammatory and skin diseases.
United States of America
ORKA
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America
OSRH

Talk to a Data Expert

Have a question? We'll get back to you promptly.